Sumo Joe, I think the great opportunity for MDI/MVP is the Continuous Flow Technology. There is a huge demand for drugs and by all accounts MVP has the technology to cost effectively increase drug production. These drugs have been mentioned in a recent article as drugs that hospitals are running out of: fentanyl, versed, propofol, and neuromuscular blockades. I wonder if CF technology can produce these drugs? I think MVP said they have a list of 100 target drugs for CF production and they have already done a trial production run of Lidocaine which has met quality standards. There is no requirement for medical trials, just produce the drugs to prescribed standards and fulfil demand. License the technology out, or build production capacity from scratch?
Opportunities for MVP in the current climate, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.85M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.5¢ | 47.5¢ | $7.631K | 15.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6981 | 48.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.0¢ | 8535 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| MVP (ASX) Chart |